Background Once-daily injections of parathyroid hormone or its amino-terminal fragments
increase bone formation and bone mass without causing hypercalcemia, but their effects on …

Since the publication of the Osteoporosis Canada guide-lines in 2002, there has been a
paradigm shift in the prevention and treatment of osteoporosis and fractures. 1, 2 The focus now …

… *Address all correspondence and requests for reprints to: Anthony B. Hodsman, Professor
of Medicine, University of Western Ontario, \#8453; St. Joseph’s Health Care, Room 2F-15, …

Background and Methods Osteoporosis is a recognized complication of corticosteroid
therapy. Whether it can be prevented is not known. We conducted a 12-month, randomized, …

Teriparatide (rDNA origin) injection [recombinant human PTH (1–34)] stimulates bone formation,
increases bone mineral density (BMD), and restores bone architecture and integrity. In …

Treatment of osteoporosis with PTH causes a marked increase in vertebral bone mineral
density (BMD). However, this effect is rapidly reversed when the treatment is stopped. The …

Knowing a person’s fracture risk according to their kidney function, gender, and age may
influence clinical management and decision-making. Using healthcare databases from Ontario, …

Objective To outline the efficacy and risks of bisphosphonate therapy for the management of
osteoporosis and describe which patients might be eligible for bisphosphonate “drug …

Using bone histomorphometry, we found that a 1‐month treatment with PTH(1–34) [hPTH(1–34)]
stimulated new bone formation on cancellous, endocortical, and periosteal bone …

BMD does not entirely explain an individual's risk of fracture. The purpose of this study was
to assess whether specific differences in spatially resolved bone composition also contribute …